title: Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
abstract: OBJECTIVE
  Women with advanced epithelial ovarian cancer are routinely treated with platinum-paclitaxel chemotherapy following cytoreductive surgery, yet only approximately 20% achieve long-term disease-free survival. We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy.
  
  
  METHODS
  To test this hypothesis, gene expression profiling of 79 primary surgically resected tumors from women with advanced-stage, high-grade epithelial ovarian cancer was done using cDNA microarrays containing 30,721 genes. Supervised learning algorithms were applied in an effort to develop a binary classifier that could discriminate women at risk for early (< or =21 months) versus late (>21 months) relapse after initial chemotherapy.
  
  
  RESULTS
  A 14-gene predictive model was developed using a set of training samples (n = 51) and subsequently tested using an independent set of test samples (n = 28). This model correctly predicted the outcome of 24 of the 28 test samples (86% accuracy) with 95% positive predictive value for early relapse.
  
  
  CONCLUSIONS
  Predictive markers for early recurrence can be identified for platinum-paclitaxel combination chemotherapy in primary ovarian carcinoma. The proposed 14-gene model requires further validation.
authors.affiliation: Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA. hartmann.lynn@mayo.edu
authors.forename: Lynn C
authors.initials: LC
authors.lastname: Hartmann
authors.forename: Karen H
authors.initials: KH
authors.lastname: Lu
authors.forename: Gerald P
authors.initials: GP
authors.lastname: Linette
authors.forename: William A
authors.initials: WA
authors.lastname: Cliby
authors.forename: Kimberly R
authors.initials: KR
authors.lastname: Kalli
authors.forename: David
authors.initials: D
authors.lastname: Gershenson
authors.forename: Robert C
authors.initials: RC
authors.lastname: Bast
authors.forename: James
authors.initials: J
authors.lastname: Stec
authors.forename: Natalia
authors.initials: N
authors.lastname: Iartchouk
authors.forename: David I
authors.initials: DI
authors.lastname: Smith
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ross
authors.forename: Sebastian
authors.initials: S
authors.lastname: Hoersch
authors.forename: Viji
authors.initials: V
authors.lastname: Shridhar
authors.forename: James
authors.initials: J
authors.lastname: Lillie
authors.forename: Scott H
authors.initials: SH
authors.lastname: Kaufmann
authors.forename: Edwin A
authors.initials: EA
authors.lastname: Clark
authors.forename: Andrew I
authors.initials: AI
authors.lastname: Damokosh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology*; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010984:Platinum / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D010984:Platinum; D017239:Paclitaxel